Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGISED-Clinic
2024-513330-38-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of amphotericin b, vancomycin and gentamicin in Crohn's disease and autoimmune colitis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jun 2025; status: authorised.
02
Drugs
amphotericin bvancomycingentamicin
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2024-513330-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513330-38-00.